16 Apr 2013, BioSpectrum Bureau , BioSpectrum
Mumbai: Themis Medicare, which is a partner firm of Australian drug delivery technology company Phosphagenics, entered into a license and supply agreement with Novartis India to sell its Themis diclofenac topical gel formulated using a unique TPM transdermal drug delivery system.
The drug delivery system is available only with Themis in India. The information was revealed by Themis Medicare in a release to the Bombay Stock Exchange (BSE) post market on Friday, April 12, 2013.
Phosphagenics welcomed the exciting commercial expansion and said that endorsement by Novartis India is a significant validation its TPM technology by a global pharmaceutical company.